Frankfurt: German BIONTECH He said the implementation was progressing well. COVID-19 shot By early autumn, the northern hemisphere will have adapted to the currently dominant virus variant, in line with government recommendations. who.
BIONTECH The CEO and co-founder said they aim for regulatory approval by the end of summer so that the seasonal vaccination campaign can begin in early fall. Ugur Shahin told shareholders at the biotech company’s annual meeting on Thursday.
BioNTech collaborates on vaccines Pfizer Even in markets outside of Greater China.a WHO Advisory Group Last week, we recommended that this year’s COVID-19 booster vaccination be updated to target one of the current mainstream infectious diseases. XBBMore Subspecies.
BioNTech/Pfizer’s new formulation is XBBMoreDeveloping variants of WHO-recommended .1.5 or XBB.1.16, Sahin added that partners would introduce ready-to-use single doses, a change from the multi-dose vials that were standard during the pandemic.
Moderna and Novavax We are also working to develop versions of the respective vaccines against XBB.1.5 and other currently circulating strains.
